Mioflex Braun

Selected form

Suxamethonium Chloride

Method of action: Muscle Relaxant

Treatment option: Anesthesia, General Anesthesia, Convulsions, Surgery

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mioflex Braun

Quick Facts

Property	Description
Active ingredient	Suxamethonium Chloride (Succinylcholine Chloride)
Form	Sterile aqueous solution for injection or infusion
Pharmacological class	Depolarizing Neuromuscular Blocker
Common use	Adjunct to general anesthesia, muscle relaxation
Origin	Synthetic (Choline derivative)

Mioflex Braun: Identity and Classification

Mioflex Braun is a potent, synthetic, prescription-only medication whose active ingredient is Suxamethonium Chloride. It belongs to the high-level pharmacological class of neuromuscular blockers, specifically known as an ultra-short acting, depolarizing agent. Its function is centered on providing a highly controlled and temporary state of skeletal muscle relaxation necessary for specialized medical procedures. The use of Suxamethonium for rapid sequence induction is clinically recognized and well-established in anesthetic practice. This indicates that the medication is highly reliable for quick and controlled muscle relaxation when time is critical.

Composition and Pharmaceutical Form

The core pharmacological entity is Suxamethonium Chloride (also widely known as Succinylcholine Chloride), a quaternary ammonium compound of synthetic origin. The medication is prepared as a sterile aqueous solution, designed exclusively for rapid parenteral administration via intravenous or, in specific situations, intramuscular injection or infusion. Chemically, its structure as a choline derivative allows it to interfere directly with nerve-to-muscle signaling at the neuromuscular junction. This form is strictly limited to hospital and critical care settings.

General Therapeutic Purpose

The overall purpose of Suxamethonium Chloride is to provide controlled, complete, and temporary loss of voluntary muscle movement. This effect is crucial for facilitating demanding medical procedures where patient movement must be instantly eliminated. Its general benefit is to serve as an adjunct to general anesthesia, primarily by assisting with the securing of the patient’s airway through the precise technique of tracheal intubation and managing muscle contractions during brief, acute interventions. The ultra-short acting nature of this agent is a key differentiating factor, making it the preferred choice for scenarios requiring rapid onset and equally rapid termination of muscle relaxation.

What side effects are possible with Mioflex Braun?

Possible side effects and safety information

The safety profile of Mioflex Braun, which contains Suxamethonium Chloride, is structured by authoritative regulatory documents based on the potential effects on major body systems. The drug's use is associated with a specific, officially documented range of adverse reactions, categorized by affected organ class.

Adverse Reaction Classifications

Adverse reactions are formally grouped by the following System-Organ Classes (SOCs):

Cardiac Disorders: Including arrhythmias, profound bradycardia, and tachycardia.
Musculoskeletal and Connective Tissue Disorders: Involving muscle fasciculations (expected initial effect), post-operative myalgia (muscle pain), and serious risks like malignant hyperthermia and acute rhabdomyolysis.
Respiratory, Thoracic and Mediastinal Disorders: Such as prolonged respiratory depression and apnea.
Metabolism and Nutrition Disorders: Specifically, the risk of hyperkalemia (high blood potassium).
Vascular Disorders: Documented changes in blood pressure (hypertension or hypotension).

Serious Adverse Reactions and Key Safety Constraints

Regulatory labeling identifies certain rare but clinically significant adverse reactions. These include Cardiac Arrest, potentially linked to hyperkalemia, and the triggering of Malignant Hyperthermia. Profound anaphylactic reactions are also officially reported.

Safety constraints exist for specific patient groups. Pediatric patients carry a heightened risk of acute rhabdomyolysis and hyperkalemia, which can lead to cardiac arrest in individuals with undiagnosed muscle conditions. Use is also restricted in patients with severe burns, multiple trauma, or extensive skeletal muscle denervation due to the high risk of severe hyperkalemia.

Time-Related Patterns

The incidence of bradycardia is greater following a second dose of Suxamethonium Chloride. For susceptible patients with trauma or burns, the risk of severe hyperkalemia is documented to typically peak approximately 7 to 10 days after the acute injury. Transient increases in intraocular pressure occur immediately following injection during the initial fasciculation phase.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

The official overdose information for Mioflex Braun (Suxamethonium Chloride) is defined by its ability to cause severe, prolonged muscle paralysis and life-threatening systemic effects. Due to the drug's nature and method of administration, any suspected overdose or severe reaction requires immediate emergency medical attention.

Documented Overdose Presentations

Classification	Official Regulatory Documentation Statement
Prolonged Paralysis	Overdose results in prolonged muscular relaxation leading to respiratory depression or apnea. The initial depolarizing block may transition into a Phase II neuromuscular block.
Cardiovascular Effects	Manifestations include serious cardiac arrhythmias, bradycardia, and the risk of cardiac arrest due to excessive hyperkalemia (high serum potassium).
Severe Outcomes	The risk of Malignant Hyperthermia is noted, requiring specific, immediate treatment with intravenous dantrolene sodium and full supportive measures.

Mandatory Emergency Actions

Seek immediate medical help for any signs of prolonged respiratory depression or severe cardiac arrhythmias.
If cardiac arrest occurs in children soon after administration, immediate treatment for hyperkalemia must be instituted.
Monitoring of neuromuscular function using a peripheral nerve stimulator is officially recommended during continuous administration to prevent overdosage.
Airway and respiratory support must be provided until the recovery of normal spontaneous respiration is confirmed.

Therapeutic Uses of Mioflex Braun

What Mioflex Braun Treats: Main Uses and Benefits

Mioflex Braun is applied across domains where additional symptomatic support is needed. The therapeutic domain is generally considered relevant for short-term use in conditions presenting with acute episodes of musculoskeletal discomfort. The application of this supportive therapy is considered relevant for use in settings marked by temporary physiological imbalance.

Managing Acute Symptom Discomfort and Intensification

This medication is often used when symptoms intensify and supportive relief is needed, particularly for symptoms related to heightened physiological activity. It provides support that helps ease the overall symptom burden, assisting with maintaining functional stability during periods of discomfort. The application of this supportive therapy is relevant in contexts involving physical discomfort, symptoms that interfere with daily functioning, and symptoms associated with acute changes. It offers symptomatic relief, assisting patients in coping more steadily with difficult episodes.

Support for Episodic Functional Strain

Mioflex Braun is applied in contexts marked by increased discomfort or tension, such as conditions involving episodic or fluctuating manifestations. It offers symptomatic relief that helps patients cope more steadily and contributes to improving day-to-day comfort during symptomatic periods by addressing symptoms that interfere with daily functioning.

Targeting Disruptive Symptom Manifestations

The medicine helps address symptom clusters that may become intense or disruptive and is relevant in situations requiring temporary assistance in symptom stabilization when symptoms create noticeable physiological strain. It supports general well-being during symptomatic phases and may assist with maintaining functional stability.

Quick Fact: Relevant for Heightened Symptoms It may assist with managing symptom clusters that become disruptive and is considered helpful in situations where the patient experiences heightened discomfort.

Regulatory References

NIH MedlinePlus overview of muscle relaxants

Eligibility and Restrictions for Use

Mioflex Braun (Suxamethonium Chloride) is a potent, prescription-only medicine with strict population eligibility requirements defined by regulatory authorities. Use is governed by explicit contraindications and conditional restrictions.

Population Status	Restrictions and Contraindications
Absolute Contraindications	The medicine must not be used in patients with a history of Malignant Hyperthermia (MH), inherited atypical plasma cholinesterase activity, pre-existing Hyperkalaemia, or skeletal muscle myopathies (e.g., muscular dystrophy). Use is also prohibited following the acute phase of major burns or trauma involving denervation.
Age-Specific Rules	Use in pediatric patients is generally reserved for emergency intubation or immediate airway procedures. Adults are eligible under standard labeled conditions, while older adults require caution due to potential co-morbidities affecting organ function.
Conditional Use	Patients with renal impairment should not receive multiple or large doses. Those with severe hepatic impairment or Myasthenia Gravis require extreme caution or are advised against use due to the risk of prolonged effects.
Pregnancy/Lactation	Use during pregnancy (e.g., Caesarean section) or lactation is only permitted when the potential benefit is judged to outweigh the potential risk, as documented in official labeling.

These official statements define the precise population boundaries within which the medicine is permitted for use.

What should I know about interactions with other medicines?

The official regulatory profile for Mioflex Braun identifies several clinically significant interaction patterns, categorized primarily by their impact on drug clearance, pharmacological effect, or procedural constraints.

Interaction with Clearance

Certain medicinal products interfere with the body's ability to clear Suxamethonium Chloride. Substances that reduce plasma cholinesterase activity—including anticholinesterase agents and some anticancer drugs—are documented in labeling to reduce clearance, resulting in a prolongation of the neuromuscular blockade. This effect is also noted to be intensified in patient populations with pre-existing reduced plasma cholinesterase activity due to factors like genetic variants or severe hepatic disease.

Pharmacodynamic and Risk Potentiation

A second category involves additive effects. Co-administration with certain volatile anesthetic agents is officially associated with an increased risk of Malignant Hyperthermia. Furthermore, specific antibiotics (such as Aminoglycosides) and certain antiarrhythmic medicines are cited in prescribing information as agents that enhance the muscle-relaxing effect.

Procedural Constraints

The drug is also subject to strict chemical incompatibility rules. Mioflex Braun must not be mixed in the same syringe with highly alkaline solutions, such as Barbiturates, as mandated by regulatory documents concerning co-administration restrictions. The combination with Cardiac Glycosides is noted to increase the risk of serious cardiac arrhythmias.

Mechanism of Action

The mechanism of action for Suxamethonium Chloride (Mioflex Braun) is strictly focused on disrupting signaling at the peripheral neuromuscular junction ( NMJ), resulting in the cessation of voluntary muscle contraction.

Molecular Blockade via Agonism and Depolarization

The drug initiates its effect by acting as an agonist at the post-synaptic Nicotinic Acetylcholine Receptor ( nAChR) on the motor endplate. This continuous activation causes the muscle membrane to remain persistently depolarized (the Phase I block), preventing the electrical potential from resetting the adjacent Voltage-gated Sodium Channels into an excitable state.

Causal Cascade Leading to Flaccid Paralysis

This sustained state of depolarization functionally blocks all further signal transmission from the nerve to the muscle fiber. The resulting membrane inexcitiability prevents the propagation of muscle action potentials, which translates physiologically into a state of flaccid paralysis across all voluntary skeletal muscles.

Mechanism Limitation by Plasma Cholinesterase

The drug's time-limited activity is governed by its rapid degradation by the enzyme Plasma Cholinesterase in the bloodstream, which allows the muscle membrane to repolarize and reset. However, genetically inherited variations in this enzyme can compromise this natural termination mechanism, leading to a mechanistic constraint that results in a prolonged period of neuromuscular blockade.

Dosage and Administration Information

Official Administration Guidelines for Mioflex Braun

Mioflex Braun (Suxamethonium Chloride) is a specialized medication whose use is strictly defined by regulatory guidelines and is limited to supervised institutional settings. Its administration requires precise dose calculation and adherence to specific procedural conditions.

Administration Routes and Scheduling

The primary method of use is parenteral. Dosage is highly individualized, based on the patient’s body weight and the duration of the required muscle relaxation.

Instruction	Details
Route of Administration	Intravenous (IV) injection (bolus or continuous infusion) or Intramuscular (IM) injection.
Typical IV Bolus	Average initial dose of 0.6 mg/kg (range 0.3 mg/kg to 1.1 mg/kg).
Continuous IV Infusion	Typically administered at a rate of 2.5 mg/min to 4.3 mg/min.
Frequency Pattern	Single dose (ultra-short duration) or intermittent/continuous infusion, strictly for the duration of the medical procedure.

Specific Use Context and Preparation

The medicine is subject to specific administrative constraints:

Procedural Requirement	Detail
Context of Use	Must be administered only after general anesthesia has induced unconsciousness.
Preparation	For infusion, the solution requires dilution to a concentration of 0.1% to 0.2% using 5% Dextrose or sterile isotonic saline.
Age-Group Rules	Pediatric dosing differs, with infants and small children typically requiring 2 mg/kg IV, while geriatric patients generally require doses comparable to younger adults.

These official instructions establish a non-negotiable framework for its institutional use, ensuring the medication is administered correctly under the necessary specialized conditions.

Recent Clinical Evidence

Mioflex Braun: Overview of Clinical Studies

The research evidence for Mioflex Braun (Suxamethonium Chloride) has been gathered over decades and is centered on its use in acute, supervised medical settings. The body of evidence consists mainly of Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate its immediate physical effects related to muscle relaxation.

Core Research Areas

The core evidence base examines the use of the medication in facilitating tracheal intubation, a critical procedure for securing a patient's airway. Research monitored immediate, short-term outcomes such as the Onset Time of muscle relaxation and the quality of Intubating Conditions. Findings describe patterns of ultra-rapid onset, a characteristic noted when comparing it to other medications in its class. Mioflex Braun is also studied as an adjunct for anesthesia to provide profound skeletal muscle relaxation measured for short-term procedures and mechanical ventilation.

Research has also evaluated its use in specialized settings, such as its role in attenuating the intensity of muscular contractions associated with procedures like Electroconvulsive Therapy (ECT).

Studies in Specific Populations and Uncertainties

Research monitored the use of Mioflex Braun in specific groups, including pediatric patients requiring emergency intubation and Obstetric Patients undergoing procedures like C-sections. Studies describe that the physiological response in these groups may vary, particularly when underlying conditions are present. For high-risk groups, uncontrolled factors from their underlying condition may influence the overall clinical picture.

Follow-up durations were strictly limited in most trials, focusing only on the immediate procedure and recovery. Consequently, long-term functional outcomes post-procedure are not fully established. Research describes that an individual’s genetic makeup related to the enzyme that processes the medication may cause a prolonged duration of muscle blockade, a factor that is not consistently predictable.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Mioflex Braun (FAQ)

Q: What are the most common side effects people report from Mioflex Braun?

Official documents describe certain effects as common or very common. Muscle fasciculation (temporary muscle twitching), post-operative muscle pains, and increased pressure in the stomach are reported as very common. Other common effects noted in regulatory information include changes in heart rate, such as profound bradycardia or tachycardia.

Q: Is there a risk of long-term side effects from using Mioflex Braun?

Because this medication is very short-acting and used only for acute procedures, clinical trials have historically focused on immediate outcomes during and shortly after the procedure. Due to this limited focus, regulatory documents describe that long-term functional outcomes following the drug's use have not been fully established in official research.

Q: What should be discussed with a healthcare provider before starting Mioflex Braun?

Official regulatory labeling emphasizes the need to review specific medical history before administration. These key points include any personal or family history of Malignant Hyperthermia, pre-existing muscle disorders, or conditions such as high blood potassium (hyperkalemia). Information regarding recent major trauma or burns, as well as severe kidney or liver conditions, is also cited in official documents as important patient history to review.

Q: Why is the information for pregnant women about Mioflex Braun often cautious?

Regulatory documents explain that plasma cholinesterase activity, an enzyme that breaks down the drug, can be naturally altered during pregnancy and shortly after childbirth. This change can potentially lead to a prolonged and intensified effect of the medication. Therefore, the official product information dictates that use is only permitted when the potential benefit for the patient is judged to outweigh the potential risk.

Q: Can Mioflex Braun be taken with common vitamins or supplements?

Official regulatory information includes a general cautionary note regarding co-administration. Regulatory information states that other substances, including herbal products or vitamin supplements, should not be taken unless they have been specifically reviewed and discussed with the prescribing healthcare professional.

Q: Is it okay to take Mioflex Braun if I have a sensitive stomach?

The official side effects list includes increased intragastric pressure (pressure inside the stomach) as a very common reaction to the medication. Since Mioflex Braun is administered only by medical professionals in a monitored, acute setting, the healthcare team is available to monitor and address potential gastrointestinal effects in the context of the procedure.

Q: Does Mioflex Braun interact with blood pressure medications?

Yes, official drug labeling documents note specific interaction patterns involving medicines used for blood pressure control. Agents such as Beta-adrenergic antagonists (Beta-blockers) and medicines like guanethidine may interact with the medication's effects, which can influence blood pressure control during administration.

Q: Can Mioflex Braun be taken alongside other pain management treatments?

Official interaction sections cite specific drug classes that can enhance the muscle-blocking effect of Mioflex Braun, including certain antiarrhythmic medicines and some antibiotics. Because of these potential interactions, the healthcare team must review all other medicines being administered, even if they are primarily for pain or other conditions.

Q: Is the use of Mioflex Braun supported by international health organizations?

Yes, the active ingredient is recognized by international bodies. It is included on the World Health Organization (WHO) Model Formulary, which lists medicines considered essential for a basic health system. It has also been assigned an international Anatomical Therapeutic Chemical (ATC) Classification number.

Q: What happens if I miss a dose of Mioflex Braun?

The medication is designed for single, acute use or continuous short-term infusion administered strictly by trained medical professionals in a highly monitored hospital setting. Because it is not a daily, self-administered medicine, the timing and amount of any dose are entirely managed by the clinical care team during the procedure.

Q: Are there any known interactions between Mioflex Braun and alcohol?

Official regulatory information indicates that the potential interaction between the active ingredient and alcohol is unknown. As with any medication administered in a supervised procedure, patients should discuss all substances, including alcohol consumption, with their healthcare team beforehand.

Q: Does Mioflex Braun require any special monitoring or blood tests?

Yes, due to certain risks, special monitoring may be necessary. Blood and urine tests may be required to check for unwanted effects and monitor kidney function. The medical team may also monitor electrolyte levels, like potassium, due to the documented risk of high potassium (hyperkalemia) associated with this medication.

Q: Does Mioflex Braun have a potential for dependency?

According to official regulatory documents, this medicine has not been reported to have habit-forming or dependency-related tendencies.

Q: Are there restrictions on driving or operating machinery while on Mioflex Braun?

Regulatory information explicitly states that the drug has an effect on the ability to drive and use machinery. Since it induces muscle paralysis and is used only as an adjunct to general anesthesia, it is administered solely within a monitored institutional setting.

Q: What is the standard warning about combining Mioflex Braun with other non-prescription drugs?

The official warnings include a general statement advising patients not to take any other medicine, including nonprescription or over-the-counter (OTC) medicines, without first discussing them with the prescribing healthcare provider.

Q: What research themes are currently being explored regarding Mioflex Braun?

While the drug is well-established, clinical research continues to explore its use in specific populations. Current themes include evaluating its role as an adjunct to general anesthesia in pediatric surgery to study locoregional analgesia techniques aimed at preventing persistent pain after the procedure.

How should Mioflex Braun be stored and disposed of?

How to Store and Dispose of Mioflex Braun

Official regulatory guidelines require precise storage conditions for Mioflex Braun (Suxamethonium Chloride) injection to ensure its stability.

Condition	Requirement (Official Labeling)
Temperature	Store in a refrigerator between 2 C and 8 C (36 F and 46 F).
Freezing	Do not freeze the solution.
Protection	Store in the original container to protect it from light.
Child Safety	Keep out of the sight and reach of children.

The solution is generally intended for immediate use upon opening; any unused portion must be discarded. Disposal of unused or expired medicine must be done strictly in accordance with local regulations for pharmaceutical waste and must not be emptied into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Portugal

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z